Revvity, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Revvity reported quarterly adjusted earnings of $1.38 per share, above the $1.30 average estimate from eighteen analysts. Revenue rose 4.3% to $728.90 million, beating the $698.15 million expected. Reported earnings per share were 56 cents, with net income of $62.3 million.

Confirmed

Global impact / market context

Higher adjusted profit and revenue than analysts expected suggest Revvity sold more equipment and controlled costs well. That matters because medical equipment sales can be uneven, and beating expectations supports the case that underlying demand and pricing remain solid, even though reported profit was lower than adjusted profit.

Analyst inference

Analysts rate the stock a hold on average, with a median price target of $160 versus the last close of $151.60. Earnings estimates rose slightly over three months with no negative revisions in the past 30 days, while the peer group carries a buy rating.

Analyst inference

What to watch

1. The gap between Revvity's adjusted earnings per share of $1.38 and reported earnings per share of 56 cents shows large adjustments; watch future filings for what those adjustments include and whether they narrow. Confirmed
2. Management could be asked whether the 4.3% revenue growth came from higher sales volume, higher prices, or acquisitions, and whether that growth can continue into the next quarter. Proposed
3. If analysts keep raising earnings estimates while the average rating stays hold, the $160 median price target may face revision, which could shift investor positioning in advanced medical equipment stocks. Analyst inference

Evidence

• Original source link unavailable